Digestive Care, Inc. Announces The Filing Of The First Module Of NDA Submission For PANCRECARB(R) (pancrelipase)

Digestive Care, Inc. (DCI) announced that it has submitted the first module of its New Drug Application (”NDA”) for PANCRECARB(R) (pancrelipase), used in the treatment of Exocrine Pancreatic Insufficiency (”EPI”), with the U.S. Food and Drug Administration (”FDA”). The FDA has granted the product Fast Track designation.

More: continued here

Filed under: Endocrinology on July 8th, 2008